Product
177Lu-LNC1003 Injection
1 clinical trial
2 indications
Clinical trial
Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-LNC1003 Injection in Adult Patients With Prostate Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Status: Not yet recruiting, Estimated PCD: 2025-11-07